Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)

RADNOR, PA / ACCESSWIRE / April 22, 2021 / Law firm Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) (“FibroGen”) that a class action lawsuit for securities fraud has been filed or sold on behalf of those who have bought and purchased FibroGen securities Put Options from November 8, 2019 through April 6, 2021 (the “Class Period”).

Lead plaintiff deadline: June 11, 2021

Website: https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogen

Contact: James Maro, Esq. (484) 270-1453

Adrienne Bell, Esq. (484) 270-1435

Toll Free (844) 887-9500

FibroGen is a biopharmaceutical company developing drugs to treat anemia, fibrotic diseases, and cancer.

The complaint alleges that throughout the class period, defendants failed to advise investors that: (1) FibroGen previously performed U.S. primary cardiovascular safety assessments from the Roxadustat Phase 3 anemia treatment program and certain related safety assessments With chronic studies submitted, kidney disease has included post hoc changes in stratification factors; (2) FibroGens analyzes with the specified stratification factors lead to higher hazard rates (point estimates of the relative risk) and 95% confidence intervals; (3) Based on these analyzes, FibroGen was unable to conclude that Roxadustat reduced (or superior to) the risk of MACE + on dialysis and of MACE and MACE + on dialysis compared to epoetin-alfa. (4) As a result, FibroGen faced significant uncertainty that its new drug application for roxadustat for the treatment of chronic kidney disease anemia would be approved by the US Food and Drug Administration. and (5) as a result of the foregoing, Defendants’ statements about the business, operations and prospects of FibroGen were materially misleading and / or unfounded.

The story goes on

FibroGen investors can attempt to be appointed as the class lead plaintiff no later than June 11, 2021 by Kessler Topaz Meltzer & Check, LLP, or other attorney, or they can choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the dispute. To be named lead plaintiff, the court must determine that the class member’s claim is typical of the claims of other class members and that the class member is adequately representing the class. Your ability to get involved in a recovery will not be affected by whether or not you will be the lead plaintiff.

Kessler Topaz Meltzer & Check, LLP, pursues class actions in state and federal courts across the country involving securities fraud, fiduciary violations, and other violations of federal and state law. Kessler Topaz Meltzer & Check, LLP, is a driving force behind corporate governance reform and has reclaimed billions of dollars on behalf of institutional and individual investors from the US and around the world. The company represents investors, consumers and whistleblowers (individuals who report fraudulent practices against the government and are involved in recovering government dollars). The complaint in this lawsuit was not filed by Kessler Topaz Meltzer & Check, LLP. Further information on Kessler Topaz Meltzer & Check, LLP can be found at www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro Jr., Esq.
Adrienne Bell, Esq.
280 Street of the King of Prussia
Radnor, PA 19087
(844) 887-9500 (toll free)
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

View source version on accesswire.com:
https://www.accesswire.com/641903/Investor-Alert-Kessler-Topaz-Meltzer-Check-LLP-Reminds-Investors-of-Securities-Fraud-Class-Action-Lawsuit-Filed-Against-FibroGen-Inc- FGEN

Comments are closed.